炎症性肠病联合治疗患者硫唑嘌呤减量:一项开放标签、前瞻性随机临床试验
在联合治疗下持续缓解的炎症性肠病患者随机分为硫唑嘌呤维持原剂量组、减半剂量组和停用组,随访1年。三组治疗失败率分别为17.9%、11.1%和30.8%(P=.1),差异无统计学意义;停用组英夫利西单抗谷浓度从4.25降至2.15 μg/mL(P=.02),减量组与原剂量组谷浓度无显著变化。作者认为减量与原剂量维持疗效相当,但停用则不然。
要点
- 联合治疗中硫唑嘌呤减半(1-1.25 mg/kg/天)1年失败率11.1%,与原剂量2-2.5 mg/kg/天组的17.9%相比差异无统计学意义。
- 停用硫唑嘌呤组失败率30.8%,英夫利西单抗谷浓度从4.25降至2.15 μg/mL(P=.02),药代动力学不利演变者占42.3%。
- 6-TGN <105 pmoles/8.108 RBC与英夫利西单抗药代动力学不利演变相关。
核心结论
- 在联合治疗下,硫唑嘌呤减量(而非停用)似乎与继续全剂量硫唑嘌呤一样有效。
研究设计与样本
- 1年开放标签、前瞻性随机临床试验,纳入联合治疗下持续缓解的炎症性肠病患者共81例。
- 随机分为三组:硫唑嘌呤维持原剂量组(2-2.5 mg/kg/天,n=28)、硫唑嘌呤减半组(1-1.25 mg/kg/天,n=27)、硫唑嘌呤停用组(n=26)。
主要发现
- 1年时治疗失败(临床复发和/或任何炎症性肠病治疗改变)例数:原剂量组5例(17.9%)、减半组3例(11.1%)、停用组8例(30.8%),三组比较P=.1。
- 英夫利西单抗中位谷浓度:原剂量组入组时3.65 vs 随访结束时3.45 μg/mL(P=.9);减半组3.95 vs 3.60 μg/mL(P=.5);停用组从4.25降至2.15 μg/mL(P=.02)。
- 英夫利西单抗药代动力学不利演变例数:原剂量组4例(14.3%)、减半组4例(14.8%)、停用组11例(42.3%)。
- 6-TGN <105 pmoles/8.108 RBC与英夫利西单抗药代动力学不利演变相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infliximab (IFX) combined with azathioprine (AZA) is more effective than IFX monotherapy in inflammatory bowel disease (IBD). AIM: To identify the AZA optimal dose that is required for efficacy when receiving combination therapy. METHODS: Patients with IBD in durable remission on combination therapy were enrolled in a 1-year, open-label, prospective trial after randomisation into three groups: AZA steady (2-2.5 mg/kg/day, n=28) vs AZA down (dose was halved 1-1.25 mg/kg/day, n=27) vs AZA stopped (n=26). Primary endpoint was failure defined as occurrence of a clinical relapse and/or any change in IBD therapy. RESULTS: Eighty-one patients were included. Five (17.9%), 3 (11.1%), and 8 (30.8%) patients experienced failure at 1 year in groups AZA steady, AZA down and AZA stopped, respectively (P=.1 across the groups). The median trough levels of IFX at inclusion were close to those measured at the end of follow-up in group AZA steady (3.65 vs 3.45 μg/mL, P=.9) and in group AZA down (3.95 vs 3.60 μg/mL, P=.5), whereas these levels dropped from 4.25 to 2.15 μg/mL (P=.02) in group AZA stopped. Four (14.3%), four (14.8%) and 11 (42.3%) patients experienced an unfavourable evolution of IFX pharmacokinetics in groups AZA steady, AZA down and AZA stopped, respectively. A threshold of 6-TGN <105 pmoles/8.108 RBC was associated with an unfavourable evolution of IFX pharmacokinetics. CONCLUSIONS: Under combination therapy, AZA dose reduction, but not withdrawal, appears to be as effective as continuation of AZA at full dose.
引用
- Roblin X, Boschetti G, Williet N, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017. PMID: 28449228. doi:10.1111/apt.14106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。